Wealth Enhancement Advisory Services’s Definium Therapeutics DFTX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$315K	Buy	9,205 +1,253	+16%	+$52.8K	﹤0.01%	3302
2026 Q2	$374K	Buy	+7,952	New	+$197K	﹤0.01%	2979
2026 Q1	–	Sell	-13,718	Closed	-$185K	–	3773
2025 Q4	$185K	Buy	13,718 +366	+3%	+$4.53K	﹤0.01%	3294
2025 Q3	$160K	Sell	13,352 -84	-0.6%	-$783	﹤0.01%	3214
2025 Q2	$96.3K	Sell	13,436 -102	-0.8%	-$671	﹤0.01%	3142
2025 Q1	$79.2K	Sell	13,538 -12	-0.1%	-$86	﹤0.01%	2802
2024 Q4	$94.3K	Buy	13,550 +3,350	+33%	+$23K	﹤0.01%	2810
2024 Q3	$58K	Buy	+10,200	New	+$70.9K	﹤0.01%	2608

Other funds holding DFTX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Patient Square Capital Menlo Park, California $627M AUM 115.4% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Wealth Enhancement Advisory Services's DFTX Position: Q3 2026 in Review

Wealth Enhancement Advisory Services increased its Definium Therapeutics (DFTX) stake by 16% in Q3 2026, buying an estimated $52.8K and bringing the position to 9,205 shares worth $315K. The position accounts for ﹤0.01% of the portfolio, ranked #3302.

Wealth Enhancement Advisory Services first reported a position in DFTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $374K in Q2 2026. 159 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

Wealth Enhancement Advisory Services held 9,205 shares of Definium Therapeutics worth $315K as of Q3 2026.
Wealth Enhancement Advisory Services bought 1,253 Definium Therapeutics shares in Q3 2026, an estimated $52.8K.
Definium Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #3302 holding.
Wealth Enhancement Advisory Services first reported a position in Definium Therapeutics in Q3 2024 and has held it in 8 quarters since.
Wealth Enhancement Advisory Services's Definium Therapeutics position peaked at $374K in Q2 2026.
159 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.